YWHAQ and Alzheimer disease: Currently, while the use of biomarkers enhances the in vivo diagnosis of AD, the approach has shifted from a syndromic model to a biological one, based on the [AT (N)] classification developed by the NIA-AA, that categorizes patients based on the presence of amyloid (A), tau protein (T), and neurodegeneration (N) (Jack et al., 2018).